Cytoagents, Inc.
Publicly observedPittsburgh, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Pittsburgh | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Cytoagents, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | CCEZCKNKL9M4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
USD 936,370.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
USD 1,313,567.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2024Publicly observed
NIH SBIR/STTR award: CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
USD 1,005,131.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.